T cell engineering with T cell receptors (TCRs) specific for tumors plays an important role in adoptive T cell transfer (ATC) therapy for cancer. Here, we present a novel strategy to redirect peripheral blood-derived αβT cells against tumors via TCRg4d1 gene transduction. The broad-spectrum antitumor activity of TCRδ1 cells in innate immunity is dependent on CDR3δ1. TCRg4d1-engineered αβT cells were prepared by lentiviral transduction and characterized by analyzing in vitro and in vivo cytotoxicity to tumors, ability of proliferation and cytokine production, and potential role in autoimmunity. Results show that TCRg4d1 genes were transduced to approximately 36% of polyclonal αβT cells. TCRg4d1-engineered αβT cells exhibited effective in vitro TCRγδ-dependent cytotoxicity against various tumor cells via the perforin-granzyme pathway. They also showed a strong proliferative capacity and robust cytokine production. TCRg4d1-engineered αβT cells neither expressed mixed TCR dimers nor bound/killed normal cells in vitro. More important, adoptive transfer of TCRg4d1-engineered αβT cells into nude mice bearing a human HepG2 cell line significantly suppressed tumor growth. Our results demonstrate a novel role for TCRg4d1 in gene therapy and ATC for cancer.
mucosa, especially the submucosal areas of the gastrointestinal, respiratory and genitourinary tracts. They recognize MHC class I-related molecules A and B (MICA and MICB) and UL-16-binding proteins (ULBPs) expressed at variable levels on epithelial tumor cells and some leukemias and lymphomas. Vδ2 T cells belong to a minor subset of the total T cell pool in the peripheral blood, responding mainly to aminobisphosphonates/synthetic phosphoantigen. (8) Due to broad-spectrum tumor recognition of TCRγδ, TCRgd gene transduction into effector T cells, such as αβT cells, may be an attractive therapeutic approach. It appears to resolve the fundamental problem of tumor targeting not found in TCRαβ. Previous studies by other groups and our laboratory have confirmed that TCRg 9d 2-transduced αβT cells, or TCRg 9d 2-modified peripheral blood mononuclear cells (PBMCs), mediate cytotoxicity against a broad range of tumor cell lines in vitro and suppress tumor growth in Daudi or SKOV3 tumor cell-bearing mice models. (9, 10) Preparing a large number of tumorreactive T cells in a short time is a major challenge for ACT in cancer patients.
interacting protein triggered CD4 + TH1 cell activation and demonstrated a cure efficacy in ACT, the method is not feasible, given the high cost and complicated process. (6) Therefore, our laboratory and other groups have pursued TCRγδ gene therapy as an alternative approach.
Compared with TCRαβ, which is highly specific for its antigen, TCRγδ displays characteristics of innate immunity, directly recognizing many stress-induced antigens in an MHC-independent manner in the early stages of inflammation and tumorigenesis. PBMCs, from healthy donors who provided informed consent, were isolated by density gradient centrifugation on Ficoll-Hypaque (TianjinHaoyang, China) and cultured in RPMI-1640 medium supplemented with 10% FCS and 200 IU/mL recombinant human interleukin-2 (IL-2).
Construction of Lentiviral Vectors and Production of Lentiviral Supernatant
The full-length sequence of TCRg 4 and TCRd 1 chains with a tumor antigenspecific CDR3 region identified from TILs of gastric carcinoma tissues was been previously described. (18) Briefly, the V region of TCRd 1 was amplified using cDNA from the TILs of gastric carcinoma tissues as a template with Vd 1-and Cd 1-specific primers, and subcloned into a pGEM-T easy vector for sequence analysis. We identified one high-frequency CDR3δ1-specific binding to gastric carcinoma tissues as a critical region (termed GTM). Finally, full-length TCRd 1 with GTM and TCRg4 chains were amplified from cDNA of gastric tumor-derived γδTILs by PCR using full-length TCRd 1 and TCRg4 primers directed at 5′-end region and 3′-end region, then cloned into pREP9 and pREP7 vectors for sequence analysis. After sequence was identified, especially for GTM, the TCRd 1 and TCRg4 genes were cloned individually and co-cloned into pCDH vectors containing the marker genes copGFP to obtain pCDH-TCRd1, pCDH-TCRg 4 and pCDH-TCRg4d1. These recombinant lentiviral vectors and pCDH vector were co-transfected into 293T cells with psPAX2 and PMD2.G vectors, respectively, using Lipofectamine 2000 (Invitrogen, USA). The lentiviral supernatant was collected, concentrated and stored at -80°C.
Generation of `aT Cells and Lentiviral Transfer
The γδT cells of PBMCs were removed by positive selection using FITC-labeled γδT-cell-specific immunomagnetic beads (Miltenyi, Germany The tumor growth inhibition ratio (D%) was estimated according to the following formula: D% = (Vc -Vt) / Vc × 100% Vc and Vt represent the means of tumor volumes of the control and treatment mice, respectively. On the last day of the experiment, the animals were euthanized by the cervical vertebra exarticulation method, and the tumors were excised and photographed. 
Cytokine Production and Proliferation Capacity
Cytokine production: Flow cytometry was used to determine the expression of IL-2 and IFN-γ in TCRg 4d 1-engineered at an effector-to-target ratio of 10:1. In comparison, mock-engineered αβT cells had significantly less cytotoxicity against LDH assay was performed to assess the cytolytic capacities of TCRf4c1-engineered `aT cells to tumor cells. We found significant cytotoxicity to HepG2 (55.78 ± 10.39%) and BGC-803 (67.36 ± 5.30%) tumor cells, and less activity against K562 tumor cells (41.33 ± 1.28%)
Statistical Analysis
Data from the in vitro experiments are presented as the mean ± standard deviation (SD). Analysis of variance and independent samples t-test were used to analyze data. For in vivo experiments, the tumor volume was assessed by analysis of variance and paired t-test, and the data are presented as the mean ± SEM. p value < 0.05 is regarded as significant.
RESULTS
The Lentiviral Vector Efficiently Transduced TCRf4c1 into Peripheral Blood-Derived `aT Cells
We previously identified a highfrequency CDR3 dominant sequence (CDR3δ1: CAFLPHADKLIFGKG), termed GTM, in TCRδ1 chain from TILs in human gastric cancer through RT-PCR and analysis of a large number of CDR3δ1 sequences. We confirmed that the CDR3δ1 peptide played a crucial role in tumor antigen recognition and bound to a wide variety of tumor cell lines and tissues similar to intact TCRγ4δ1. (18) The full-length TCRδ1 with GTM and TCRγ4 chains were amplified from cDNA of a gastric tumorderived γδTILs by PCR and paired to form TCRγ4δ1 (18) (Figure 1A) . Using the amplified TCRd 1 and TCRg4 DNAs from pREP9-TCRδ1 with GTM and pREP7-TCRg 4, we constructed pCDH-TCRg4d 1, a lentiviral vector harboring the TCRδ1 and TCRγ4 chain DNAs. The TCRg4 gene was controlled by the cytomegalovirus (CMV) promoter ( Figure 1B) .
To examine whether peripheral bloodderived αβT cells can be lentivirally engineered with TCRg 4d 1, a lentiviral vector with TCRg 4d 1 was transduced into pre-activated peripheral bloodderived αβT cells. TCRγ4δ1 expression was determined by staining with specific TCRγδ and TCRαβ antibodies. Approximately 36% of polyclonally activated αβT cells expressed TCRγ4δ1 ( Figure 1C ), indicating that TCRg 4d 1s were efficiently transduced. Figure 2D ). These data suggest that TCRg 4d 1-engineered αβT cells kill tumor cells via the perforin-granzyme pathway.
TCRf4c1-engineered `aT cells produced cytokines IL-2 and IFN-f when stimulated by HepG2 tumor cells. The cytokines IL-2 and IFN-γ play important roles in antitumor activity. (22, 23) We analyzed the IL-2 and IFN-γ expression of resting and nonresting TCRg 4d 1-engineered αβT cells and mock-engineered αβT cells by flow cytometry after incubation with HepG2 tumor cells and treatment with BFA for 6 h. Results show that the percentage of restingTCRg 4d 1-engineered αβT cells expressing IL-2 and IFN-γ was 30.38% and 31.56%, respectively, higher than control groups (9.49% and 10.43%, respectively; Figure 3A ). The percentage of nonresting TCRg 4d 1-engineered αβT cells producing IL-2 and IFN-γ was 33.66% and 31.16%, respectively, higher than the control group (14.63% and 10.78%, respectively; Figure 3B ). Two different statuses of TCRg 4d 1-engineered αβT cells produced similar amounts of cytokines. In addition, TCRg 4d 1-engineered αβT cells expressed Ki67, a proliferation marker, significantly higher than control after stimulation with anti-γδTCR antibody ( Figure 3C ). These findings indicate that TCRg 4d 1-engineered αβT cells TCRγ4δ1 was expressed on the surface of TCRg 4d 1-engineered αβT cells ( Figure 4A ). These data suggest that the introduced TCRγ4 or TCRδ1 chains did not pair with the endogenous TCRα or TCRβ chains to generate mixed TCR dimers. This feature would be beneficial in reducing the risk of autoimmunity. We also assessed the binding activity of TCRγ4δ1-Fc and the cytotoxicity of TCRg 4d 1-engineered αβT cells to some normal cells by flow cytometry and LDH assay. We found that TCRγ4δ1-Fc did not bind to PBMCs, 1308.1.86, ccc-HEL-1 or 293T cells ( Figure 4B ). The cytotoxicity of TCRg 4d 1-engineered αβT cells toward PBMCs, 1308.1.86, ccc-HEL-1 and 293T cells was 2.79% ± 2.04%, 8.11% ± 3.52%, 11.57% ± 1.89% and 15.53% ± 0.68% at an effectorto-target ratio of 10:1, respectively, compared with 4.04% ± 0.54% (p = 0.365), 9.10% ± 6.14% Figures 5A and C) . The tumor growth inhibition ratio was calculated, and its curve is illustrated in Figure 5B . with severe inflammation should avoid adoptive TCRg 4d 1-engineered αβT cell transfer therapy unless inflammation is eliminated. These stress-induced molecules are rarely expressed on normal cells under physiological conditions. Most normal human tissues do not express MICA, but glandular and gastric epithelial cells do, which occurred in the intracellular location and was not transported to the cell surface. (23, 48, 49) The main challenge of this study was to improve the transduction rate and expression level of TCRγ4δ1 in αβT cells. Previous reports suggested that the creation of high-avidity TCR-engineered T cells mediate antitumor reactivity in a TCR-dependent manner, driven by the binding of TCR with tumor antigen. Therefore, it is of utmost importance to screen for T cell receptors with a high affinity for tumor antigen and a broad spectrum of tumor recognition. Previously, we identified a high-frequency CDR3 sequence in the TCRδ1 chain from TILs in human gastric cancer and found that this CDR3 was crucial to antigen recognition. We also found that TCRγ4δ1-Fc fusion proteins had a strong binding ability to the tumor-associated antigens MICA and UL-16 binding protein 5 (ULBP5) via ELISA and SPR assays. (18) These results suggest that TCRγ4δ1 possess a high affinity to antigen recognition. In addition, multiple tumor-expressed antigens, such as MICA, MHC class I chain-related molecules B (MICB) and various ULBPs, are recognized by the TCR of human Vδ1 T cells and are constitutively expressed at variable levels on many epithelial tumor cells and some leukemias and lymphomas. (19, 34, 35) We therefore explored the binding ability of TCRγ4δ1 and a variety of tumors, particularly epithelial tumors. Our previous study reported that TCRγ4δ1 displayed strong binding to BGC-823, G401, GLC-82, HT29 and SKOV3 cells and tissues. (18) In this study, we found consistent results showing that TCRγ4δ1s also significantly bound other tumor cells, including HepG2, BGC-803, K562 (Figures 2A  and B) . Our results support the notion that TCRγ4δ1 recognizes a large panel of tumors, especially epithelium-derived tumors. In summary, TCRγ4δ1 has a broad spectrum of tumor recognition.
T cells was determined by the TCR cell-surface makeup of T cells, and that transport of the TCR to the plasma membrane depended on complete assembly of the TCR/CD3 complex. (24, 50) In TCRg 4d 1-engineered αβT cells, competition between TCRγ4δ1 and TCRαβ for association with CD3 could restrict their expression levels on the cell surface. Thus, the upregulation of TCRγ4δ1 cell surface expression is advantageous in reducing the surface expression of endogenous TCRαβ. In summary, the increased transduction rate and expression level of TCRγ4δ1 in αβT cells will enhance the efficacy of TCRg 4d 1-engineered αβT cells and decrease the risk of autoimmunity resulting from allologous TCRαβ recognition.
CONCLUSION
Our results highlight a novel TCRgd -engineering αβT cell-effector ACT therapy for solid tumors, with safety and strong antitumor efficacy, and with the clinical potential to treat cancer patients.
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